Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Neurocrine Biosciences is a biopharmaceutical company specializing in neuroscience. It develops and commercializes treatments for neuropsychiatric, neurological, and neuroendocrine disorders, including FDA-approved drugs like INGREZZA for tardive dyskinesia and Huntington's chorea, and CRENESSITY for congenital adrenal hyperplasia. The company focuses on innovative pipelines across small molecules, peptides, proteins, antibodies, and gene therapies, serving global markets with a competitive edge in rare and underserved neurological conditions.
This description was generated via AI from an annual report. Updated about 1 year ago.